Reapit Raises $27.1M in Growth Funding

Climingo

Climingo helps ensure organisations are using the best weather data available. We benchmark vendor accuracy for customer locations and use cases, then help them procure the right provider with confidence. Founded through Carbon13 by co-founders Dr Avi Baruch and Alper Dincer, we bring together over 30 years of experience in weather and climate evaluation, shaped by first-hand experience of how critical data choices impact real world decisions

Redx Pharma

Redx Pharma is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases Our team of scientists are based at our labs at Alderley Park, Cheshire, the UK’s largest single site life science campus. The team is made up of world class medicinal chemistry, biology and clinical capability with deep-rooted biotech and large pharma experience. Redx's lead asset, the selective ROCK2 inhibitor, zelasudil (RXC007), is in development for idiopathic pulmonary fibrosis and commenced a Phase 2 clinical trial in Q4 2022. Redx’s second ROCK inhibitor candidate, RXC008, a GI-targeted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn’s disease, commenced a Phase 1 clinical trial in Q1 2024. The Company's lead oncology product candidate, the Porcupine inhibitor, zamaporvint (RXC004), commenced a Phase 2 programme in November 2021. The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. Read more about our company at https://www.redxpharma.com/about-us/ If you're interested in joining us, please visit https://www.redxpharma.com to see what job vacancies we currently have.

Fraiya Ultrasound

At Fraiya Ltd, our mission is to revolutionize the field of ultrasound through cutting-edge artificial intelligence technology. Fraiya aims to elevate the standard of prenatal care by advancing the accuracy, consistency, and efficiency of ultrasound, supporting more confident clinical decisions and a more reassuring experience for every mother and baby. The Fraiya Platform is designed to work together across the prenatal pathway, starting with the anomaly scan, to improve consistency, reduce workload and raise the standard of care.